Catalyst Biosciences Inc.
| NASDAQ: CBIO | Healthcare / Biotechnology / USA |
| 0.4529 | -0.0370 | -7.55% | Vol 153.07K | 1Y Perf -5.95% |
| Oct 3rd, 2023 16:00 DELAYED |
| BID | 0.4392 | ASK | 0.5186 | ||
| Open | 0.4800 | Previous Close | 0.4899 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 9.00 | Analyst Rating | Hold 3.00 | |
| Potential % | 1.89K | Finscreener Ranking | ★★★★★ 62.29 | |
| Insiders Trans % 3/6/12 mo. | -/100/100 | Value Ranking | ★★★★★ 64.55 | |
| Insiders Value % 3/6/12 mo. | -/100/100 | Growth Ranking | ★★★★★ 77.94 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/100/100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 47.92 | Earnings Rating | Buy | |
| Market Cap | 17.20M | Earnings Date | 13th Nov 2023 | |
| Alpha | 0.22 | Standard Deviation | 1.31 | |
| Beta | -5.08 |
Today's Price Range 0.44850.4899 | 52W Range 0.18870.7400 | 5 Year PE Ratio Range -1.70-0.9000 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | -2.64% | ||
| 1 Month | 7.74% | ||
| 3 Months | 39.97% | ||
| 6 Months | 133.29% | ||
| 1 Year | -5.95% | ||
| 3 Years | -89.23% | ||
| 5 Years | -95.57% | ||
| 10 Years | -99.89% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -61.58 | |||
ROE last 12 Months | 29.40 | |||
ROA (5Y Avg) | -50.04 | |||
ROA last 12 Months | 24.36 | |||
ROC (5Y Avg) | -57.90 | |||
ROC last 12 Months | 25.10 | |||
Return on invested Capital Q | -9.37 | |||
Return on invested Capital Y | -38.15 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.20 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.70 | ||||
| 0.82 | ||||
| 24.42 | ||||
| - | ||||
| -0.30 | ||||
| -1.56 | ||||
| 0.82 | ||||
| 0.78 | ||||
| 1.46M | ||||
| Forward PE | -16.07 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 17.10 | ||||
| 18.40 | ||||
| 0.01 | ||||
| 0.01 | ||||
| 11.88K | ||||
| Leverage Ratio | 1.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.60 | ||||
| 366.90 | ||||
| 377.20 | ||||
| -201 808.00 | ||||
| -92.78 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 794.00K | ||||
| 0.03 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -0.07 | -0.07 | 0.00 |
| Q02 2022 | -0.22 | -0.18 | 18.18 |
| Q01 2022 | -0.56 | -0.46 | 17.86 |
| Q04 2021 | -0.54 | -0.64 | -18.52 |
| Q03 2021 | -0.66 | -0.80 | -21.21 |
| Q02 2021 | -0.68 | -0.64 | 5.88 |
| Q01 2021 | -0.77 | -0.79 | -2.60 |
| Q04 2020 | -0.89 | -0.86 | 3.37 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2023 QR | -0.05 | 0.00 | - |
| 12/2023 QR | -0.04 | 20.00 | Positive |
| 12/2023 FY | -0.16 | 0.00 | - |
| 12/2024 FY | -0.03 | 80.00 | Positive |
| Next Report Date | 13th Nov 2023 |
| Estimated EPS Next Report | -0.05 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 153.07K |
| Shares Outstanding | 37.97K |
| Shares Float | 27.23M |
| Trades Count | 389 |
| Dollar Volume | 70.88K |
| Avg. Volume | 229.21K |
| Avg. Weekly Volume | 95.96K |
| Avg. Monthly Volume | 198.74K |
| Avg. Quarterly Volume | 392.95K |
Catalyst Biosciences Inc. (NASDAQ: CBIO) stock closed at 0.4899 per share at the end of the most recent trading day (a 1.58% change compared to the prior day closing price) with a volume of 122.68K shares and market capitalization of 17.20M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 34 people. Catalyst Biosciences Inc. CEO is Nassim Usman.
The one-year performance of Catalyst Biosciences Inc. stock is -5.95%, while year-to-date (YTD) performance is -7.13%. CBIO stock has a five-year performance of -95.57%. Its 52-week range is between 0.1887 and 0.74, which gives CBIO stock a 52-week price range ratio of 47.92%
Catalyst Biosciences Inc. currently has a PE ratio of 1.70, a price-to-book (PB) ratio of 0.82, a price-to-sale (PS) ratio of 24.42, a price to cashflow ratio of -, a PEG ratio of -, a ROA of 24.36%, a ROC of 25.10% and a ROE of 29.40%. The company’s profit margin is -92.78%, its EBITDA margin is 377.20%, and its revenue ttm is $794.00 Thousand , which makes it $0.03 revenue per share.
Of the last four earnings reports from Catalyst Biosciences Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.05 for the next earnings report. Catalyst Biosciences Inc.’s next earnings report date is 13th Nov 2023.
The consensus rating of Wall Street analysts for Catalyst Biosciences Inc. is Hold (3), with a target price of $9, which is +1 887.19% compared to the current price. The earnings rating for Catalyst Biosciences Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Catalyst Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Catalyst Biosciences Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 10.11, ATR14 : 0.04, CCI20 : -78.97, Chaikin Money Flow : 0.07, MACD : 0.00, Money Flow Index : 59.07, ROC : -12.19, RSI : 48.50, STOCH (14,3) : 20.95, STOCH RSI : 0.43, UO : 39.67, Williams %R : -79.05), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Catalyst Biosciences Inc. in the last 12-months were:
Catalyst Biosciences Inc.
Catalyst Biosciences Inc is a clinical-stage biopharmaceutical company. It mainly focuses on developing novel medicines to address serious medical conditions for individuals in need of treatment options. The company emphasizes on product development efforts in the field of hemostasis and to develop valuable therapies for individuals with hemophilia. It is engaged in clinical development of improved, next-generation subcutaneous prophylaxis using enhanced potency Factor VIIa and Factor IX variants.
CEO: Nassim Usman
Telephone: +1 650 871-0761
Address: 611 Gateway Boulevard, South San Francisco 94080, CA, US
Number of employees: 34
